6.250GBp0.00%Mkt Cap: 72.66M $P/E: —1d ago
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Fera…
Industry Peers
Drug Manufacturers - Specialty & GenericIndicators:|
Key Statistics
Company
Market Cap72.66M $
Enterprise Value92.71M $
Revenue (TTM)54.02M $
Gross Profit25.04M $
Net Income (TTM)-19.19M $
Revenue/Share0.0511 USD
Last Price6.250 GBp
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees61
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)8.33
PEG—
EV/EBITDA-8.68
EV/Revenue1.72
P/S1.34
P/B-5.91
EPS (TTM)-0.02
EPS (Forward)0.01
52W Range
3.40031% of range12.50
52W High12.50 GBp
52W Low3.400 GBp
Profitability
Gross Margin46.36%
Oper. Margin-15.07%
EBITDA Margin-19.76%
Profit Margin-35.52%
ROE117.10%
ROA-27.07%
Growth
Revenue Growth40.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.67M $
CapEx (TTM)326.09K $
FCF Margin12.56%
FCF Yield9.34%
Net Debt20.12M $
Net Debt/EBITDA-1.88
Balance Sheet
Debt/Equity-2.00
Current Ratio0.90
Quick Ratio0.67
Book Value/Sh-0.0106 GBp
Cash/Share0.0110 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)16.67 GBp
Upside (mean)+166.7%
Target Range12.00 GBp – 23.00 GBp
GBp12.00+166.7% to meanGBp23.00
# Analysts3
Ownership
Shares Out.1.07B
Float411.58M
Insiders61.77%
Institutions3.34%
Technical
SMA 506.305 (-0.9%)
SMA 2008.436 (-25.9%)
Beta1.76
S&P 52W Chg20.25%
Avg Vol (30d)1.02M
Avg Vol (10d)955.59K
Technical Indicators
RSI (14)47.5
MACD-0.0521
MACD Signal-0.0844
MACD Hist.+0.0323
BB Upper6.564 GBp
BB Middle6.255 GBp
BB Lower5.946 GBp
BB Width9.89%
ATR (14)0.3624 GBp
Vol Ratio (20d)0.06x